长春高新(000661) - 2015 Q1 - 季度财报

Financial Performance - Revenue for the first quarter reached ¥518,899,249.16, an increase of 16.56% compared to ¥445,190,968.46 in the same period last year[7] - Net profit attributable to shareholders was ¥96,184,646.54, representing a 47.67% increase from ¥65,133,012.41 year-over-year[7] - Basic earnings per share rose to ¥0.73, up 46.00% from ¥0.50 in the previous year[7] - The company's net profit attributable to shareholders increased by 47.67% year-on-year due to growth in pharmaceutical revenue and real estate settlement income[14] Cash Flow and Investments - The net cash flow from operating activities decreased by 18.95% to ¥55,725,538.66, down from ¥68,756,325.01[7] - Cash outflow from investment activities increased by 63.05% to 12,713,382.38 CNY, due to higher spending on fixed assets and long-term assets[16] - The net cash flow from financing activities decreased by 292.71% to a loss of 54,312,274.50 CNY, mainly due to increased dividend payments to minority shareholders[16] - The net decrease in cash and cash equivalents was 79,956,863.04 CNY, a decline of 265.16% due to higher dividend distributions[17] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥3,118,189,450.41, a slight decrease of 0.96% from ¥3,148,423,175.63 at the end of the previous year[7] - Net assets attributable to shareholders increased by 6.59% to ¥1,556,396,659.33, compared to ¥1,460,212,012.79 at the end of the last year[7] - The total number of ordinary shareholders at the end of the reporting period was 11,726[10] - The largest shareholder, Changchun Gaoxin Chaoda Investment Co., Ltd., held 22.28% of the shares, amounting to 29,260,367 shares[10] Expenses and Costs - Operating costs increased by 51.76% to 40,576,629.45 CNY, primarily due to higher settlement income from the real estate sector[15] - Development expenses rose by 41.94% to 7,422,828.10 CNY, reflecting increased spending on new drug development[14] - Tax expenses grew by 72.06% to 13,125,873.93 CNY, attributed to an increase in total profit[15] Other Financial Metrics - The weighted average return on equity improved to 6.38%, up from 5.18% in the previous year[7] - The company reported non-recurring gains and losses totaling ¥366,587.40 for the period[8] - Financial assets measured at fair value decreased by 100% to a loss of 179,550.00 CNY due to the sale of financial assets[14]